April 2 (Reuters) - The U.S. Food and Drug Administration have missed the deadline for making a key decision on Novavax's NVAX.O COVID-19 vaccine, the Wall Street Journal reported on Wednesday, citing people familiar with the matter.
(Reporting by Bhanvi Satija in Bengaluru; Editing by Shreya Biswas)
((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91 9873062788;))